Analysis of Revenues
Paying user area
Try for free
Allergan PLC pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Allergan PLC, income statement, revenues
US$ in thousands
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
- US Specialized Therapeutics
- The revenue for US Specialized Therapeutics exhibited a consistent upward trend from 2015 through 2018, increasing from $4,309.8 million to $6,920.3 million. However, in 2019, there was a slight decline to $6,820.0 million, indicating a minor downturn after years of growth.
- US General Medicine
- This segment showed a general downward trend over the five-year period, decreasing from $6,338.4 million in 2015 to a low of $5,322.9 million in 2018. In 2019, there was a moderate recovery to $5,834.9 million, suggesting some regained momentum but still below 2015 levels.
- International
- International revenues increased steadily from $2,187.3 million in 2015 to $3,504.7 million in 2018, reflecting consistent growth in overseas markets. A slight contraction occurred in 2019, with revenues falling to $3,402.0 million.
- Anda Distribution
- Revenue data for Anda Distribution is only reported for 2015 at $2,225.4 million, with no available information for subsequent years, preventing trend analysis for this segment.
- Segment Revenues
- Total segment revenues fluctuated over the period, starting at $15,060.9 million in 2015, dipping to $14,616.9 million in 2016, then rising to a peak of $15,919.3 million in 2017. A small decline to $15,747.9 million occurred in 2018, followed by an increase to $16,056.9 million in 2019, indicating overall growth with some volatility.
- Corporate Revenues
- Corporate revenues were relatively minimal in scale and showed variability. After a small positive amount in 2015 ($10.1 million), there was a negative value in 2016 (-$46.3 million), followed by positive figures in 2017 ($21.4 million), 2018 ($39.5 million), and 2019 ($32.0 million). This suggests occasional non-operational impacts affecting corporate revenue figures.
- Net Revenues
- Net revenues largely mirrored the segment revenues trend, starting at $15,071.0 million in 2015, declining to $14,570.6 million in 2016, then increasing sharply to $15,940.7 million in 2017. A slight decline was observed in 2018 ($15,787.4 million), followed by growth to $16,088.9 million in 2019. The data indicates a generally positive growth trajectory with some yearly fluctuations.